OPG/RANKL
Open Access
- 15 January 2008
- journal article
- abstracts
- Published by EDP Sciences in médecine/sciences
- Vol. 24 (1) , 105-110
Abstract
Given the increasing risk of fractures with aging in western countries, there is a need for the development of safe and efficient anti-osteoporotic drugs for the prevention and treatment of osteoporosis. Recent studies have provided evidence for an essential role of RANKL (Receptor Activator of Nuclear Factor-kappa B Ligand) and its decoy receptor osteoprotegerin in the control of osteoclast differentiation and survival. Post-menopausal osteoporosis results from an imbalance between resorption and formation associated with decreased OPG/RANKL. Targeting the OPG/RANKL system may therefore have a beneficial impact in osteoporosis. Accordingly, the development of novel strategies targeting OPG/RANKL using anti-RANKL or therapeutic intervention proved to be efficient to reduce bone resorption and to prevent bone loss in postmenopausal osteoporosis. This opens the way for novel therapeutic strategies for correcting bone metabolism in various pathologic disorders characterized by increased bone remodelling and bone loss.Keywords
This publication has 27 references indexed in Scilit:
- RANKL–RANK signaling in osteoclastogenesis and bone diseaseTrends in Molecular Medicine, 2006
- Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL–RANK signaling systemImmunological Reviews, 2005
- Drugs Used to Treat Osteoporosis: The Critical Need for a Uniform Nomenclature Based on Their Action on Bone RemodelingJournal of Bone and Mineral Research, 2005
- PTH Differentially Regulates Expression of RANKL and OPGJournal of Bone and Mineral Research, 2004
- Osteoclast differentiation and activationNature, 2003
- Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormoneJournal of Cellular Biochemistry, 2003
- Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expressionExperimental & Molecular Medicine, 2002
- Différenciation, fonction et contrôle de l’ostéoblastemédecine/sciences, 2001
- Adenoviral Delivery of Osteoprotegerin Ameliorates Bone Resorption in a Mouse Ovariectomy Model of OsteoporosisMolecular Therapy, 2001
- Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand FamiliesEndocrine Reviews, 1999